PUBLIC COMPANY
saveActio Biosciences Inc
updated 21d ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 1
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
- Jazz to buy rare epilepsy drugmaker in potentially $1.3B dealActio Biosciences, which will receive $820 million up front in the deal, adds to a major upswing in private biotech buyouts seen throughout this year.biopharma_dive · 10d ago
- Jazz commits up to $1.3B to buy Actio, bolster epilepsy pipelineJazz Pharmaceuticals is reaching into its wallet once again, this time buying Actio Biosciences and an experimental therapy for KCNT1+ epilepsy, a form of the disease with no FDA-approved treatments.biospace · 10d ago
- Jazz bets on epilepsy again by acquiring Actio for $820M upfrontJazz Pharmaceuticals will buy Actio Biosciences for $820 million upfront and up to $500 million more if certain milestones are met for its ultra-rare epilepsy drug. The deal further solidifies Jazz…endpoints · 10d ago
- STAT+: Pharmalittle: We’re reading about a Sanofi drug shortage, a Jazz Pharma deal, and moreSanofi is experiencing shortages of two medicines used to treat Pompe disease after the FDA warned the company over manufacturing issuesstat · 10d ago
- Jazz pays $820M to buy Actio, adding clinical-stage asset to orchestra of epilepsy therapiesJazz Pharmaceuticals is adding to its orchestra of epilepsy treatments with the acquisition of Actio Biosciences for $820 million upfront.fiercebiotech · 11d ago
comments(0)
5-min edit window · permanent after that